FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2133279561> ?p ?o ?g. }

• W2133279561 endingPage "5800" @default.
• W2133279561 startingPage "5794" @default.
• W2133279561 abstract "CASP-3 gene gives rise, by alternative splicing to a caspase-3s variant, to the antagonist apoptotic property of caspase-3. Deregulation of splicing in tumor cells favoring the expression of antiapoptotic variants has been reported to contribute to both tumorigenesis and chemoresistance. Thus, we investigated the role of caspase-3 and its splice variant in breast cancer cells.Breast tumor cell lines deficient (MCF-7) and proficient (HBL100) for CASP-3 gene were transfected with each transcript and were characterized for their apoptotic response to cyclophosphamide. Expression of the two transcripts were measured by reverse transcription-PCR in 130 breast carcinomas, including 90 locally advanced tumors treated with neoadjuvant chemotherapy containing cyclophosphamide, epirubicine, and 5-fluorouracil.Overexpression of caspase-3s variant in caspase-3-transfected cell lines significantly inhibits apoptosis induced by cyclophosphamide (P < 0.0001 for both cell lines). In breast tissues, only caspase-3 levels were higher in carcinomas than in corresponding adjacent normal tissues (P = 0.0396). Locally advanced carcinomas with high levels of caspase-3 (P < 0.0001) and weak levels of caspase-3s (P = 0.0248) were more sensitive to treatment. Therefore, increase in caspase-3s/caspase3 ratio expression was significantly associated with chemoresistance (P = 0.01). Logistic univariate and multivariate analyses realized according to pathologic response confirm that increased caspase-3s expression was indicative of chemoresistance (P = 0.012 and P = 0.026, respectively).The results agree with an antagonist function between the two transcripts of caspase-3 and show that their ratio of expression levels may define a subset of locally advanced breast cancer patients who are more likely to benefit from neoadjuvant cyclophosphamide-containing chemotherapy." @default.
• W2133279561 created "2016-06-24" @default.
• W2133279561 creator A5003722893 @default.
• W2133279561 creator A5046253661 @default.
• W2133279561 creator A5051312305 @default.
• W2133279561 creator A5058950022 @default.
• W2133279561 creator A5064556770 @default.
• W2133279561 creator A5067812071 @default.
• W2133279561 date "2006-10-01" @default.
• W2133279561 modified "2023-10-11" @default.
• W2133279561 title "Overexpression of Caspase-3s Splice Variant in Locally Advanced Breast Carcinoma Is Associated with Poor Response to Neoadjuvant Chemotherapy" @default.
• W2133279561 cites W1604468403 @default.
• W2133279561 cites W1616649922 @default.
• W2133279561 cites W1916777863 @default.
• W2133279561 cites W1935077308 @default.
• W2133279561 cites W1969652248 @default.
• W2133279561 cites W1984207100 @default.
• W2133279561 cites W1991982116 @default.
• W2133279561 cites W1992278118 @default.
• W2133279561 cites W1993414868 @default.
• W2133279561 cites W2000669087 @default.
• W2133279561 cites W2013920437 @default.
• W2133279561 cites W2028582699 @default.
• W2133279561 cites W2045563337 @default.
• W2133279561 cites W2055470380 @default.
• W2133279561 cites W2059236352 @default.
• W2133279561 cites W2064558158 @default.
• W2133279561 cites W2071987213 @default.
• W2133279561 cites W2111173714 @default.
• W2133279561 cites W2119270486 @default.
• W2133279561 cites W2135196225 @default.
• W2133279561 cites W2135589851 @default.
• W2133279561 cites W2149935933 @default.
• W2133279561 cites W2155779256 @default.
• W2133279561 cites W2319173743 @default.
• W2133279561 cites W4252995669 @default.
• W2133279561 cites W2038080098 @default.
• W2133279561 doi "https://doi.org/10.1158/1078-0432.ccr-06-0725" @default.
• W2133279561 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/17020986" @default.
• W2133279561 hasPublicationYear "2006" @default.
• W2133279561 type Work @default.
• W2133279561 sameAs 2133279561 @default.
• W2133279561 citedByCount "61" @default.
• W2133279561 countsByYear W21332795612012 @default.
• W2133279561 countsByYear W21332795612013 @default.
• W2133279561 countsByYear W21332795612014 @default.
• W2133279561 countsByYear W21332795612015 @default.
• W2133279561 countsByYear W21332795612016 @default.
• W2133279561 countsByYear W21332795612017 @default.
• W2133279561 countsByYear W21332795612018 @default.
• W2133279561 countsByYear W21332795612019 @default.
• W2133279561 countsByYear W21332795612020 @default.
• W2133279561 countsByYear W21332795612021 @default.
• W2133279561 countsByYear W21332795612022 @default.
• W2133279561 countsByYear W21332795612023 @default.
• W2133279561 crossrefType "journal-article" @default.
• W2133279561 hasAuthorship W2133279561A5003722893 @default.
• W2133279561 hasAuthorship W2133279561A5046253661 @default.
• W2133279561 hasAuthorship W2133279561A5051312305 @default.
• W2133279561 hasAuthorship W2133279561A5058950022 @default.
• W2133279561 hasAuthorship W2133279561A5064556770 @default.
• W2133279561 hasAuthorship W2133279561A5067812071 @default.
• W2133279561 hasConcept C104317684 @default.
• W2133279561 hasConcept C105580179 @default.
• W2133279561 hasConcept C121608353 @default.
• W2133279561 hasConcept C12519072 @default.
• W2133279561 hasConcept C126322002 @default.
• W2133279561 hasConcept C190283241 @default.
• W2133279561 hasConcept C194583182 @default.
• W2133279561 hasConcept C2776694085 @default.
• W2133279561 hasConcept C2776755627 @default.
• W2133279561 hasConcept C31573885 @default.
• W2133279561 hasConcept C502942594 @default.
• W2133279561 hasConcept C530470458 @default.
• W2133279561 hasConcept C54009773 @default.
• W2133279561 hasConcept C54355233 @default.
• W2133279561 hasConcept C54458228 @default.
• W2133279561 hasConcept C555283112 @default.
• W2133279561 hasConcept C67705224 @default.
• W2133279561 hasConcept C71924100 @default.
• W2133279561 hasConcept C81885089 @default.
• W2133279561 hasConcept C86803240 @default.
• W2133279561 hasConcept C98424977 @default.
• W2133279561 hasConceptScore W2133279561C104317684 @default.
• W2133279561 hasConceptScore W2133279561C105580179 @default.
• W2133279561 hasConceptScore W2133279561C121608353 @default.
• W2133279561 hasConceptScore W2133279561C12519072 @default.
• W2133279561 hasConceptScore W2133279561C126322002 @default.
• W2133279561 hasConceptScore W2133279561C190283241 @default.
• W2133279561 hasConceptScore W2133279561C194583182 @default.
• W2133279561 hasConceptScore W2133279561C2776694085 @default.
• W2133279561 hasConceptScore W2133279561C2776755627 @default.
• W2133279561 hasConceptScore W2133279561C31573885 @default.
• W2133279561 hasConceptScore W2133279561C502942594 @default.
• W2133279561 hasConceptScore W2133279561C530470458 @default.
• W2133279561 hasConceptScore W2133279561C54009773 @default.
• W2133279561 hasConceptScore W2133279561C54355233 @default.
• W2133279561 hasConceptScore W2133279561C54458228 @default.

• next